Alzamend Neuro Inc

ALZN | $0.6894 -0.23% -0.23% 28K

(0.0% 1d) (-35.2% 1m) (13.3% 1y) (-1.4% 2d) (-1.4% 3d) (-8.2% 7d) (3.58% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 4,734,004
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

BriaCell Therapeutics Corp.

BCTX | $2.19 -5.6% -5.94% 140K

Professional, Scientific, and T...

(0.0% 1d) (21.1% 1m) (-62.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 34,999,980
https://www.briacell.com
Sec Filling | Patents | 2022 employees

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

cancer

add to watch list Paper trade email alert is off

Monte Rosa Therapeutics Inc

GLUE | $5.84 -1.35% -1.37% 110K

Professional, Scientific, and T...

(0.0% 1d) (-22.9% 1m) (2.3% 1y) (0.0% 2d) (0.9% 3d) (-11.0% 7d) (5.5% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 292,876,000
https://www.monterosatx.com
Sec Filling | Patents | 60 employees

Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.

drug discovery profitable computational machine learning

add to watch list Paper trade email alert is off

Graphite Bio Inc

GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (14.0% 1y) (0.0% 2d) (-2.8% 3d) (0.0% 7d) (-33.57% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 190,434,748
https://graphitebio.com
Sec Filling | Patents | 27 employees

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

gene therapies

add to watch list Paper trade email alert is off

Nautilus Biotechnology Inc

NAUT | $2.46 5.13% 4.88% 53K

Professional, Scientific, and T...

(0.0% 1d) (-10.9% 1m) (-2.4% 1y) (0.0% 2d) (1.2% 3d) (0.0% 7d) (-31.3% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 307,741,277

Sec Filling | Patents | 134 employees

born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. the extraordinary team at nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

diagnostics chip

add to watch list Paper trade email alert is off

Panbela Therapeutics Inc

PBLA | $0.4895 -6.31% 66K

Professional, Scientific, and T...

(0.0% 1d) (-34.4% 1m) (-97.0% 1y) (0.0% 2d) (-19.2% 3d) (-22.2% 7d) (363.69% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 2,376,454
http://www.sunbiopharma.com/
Sec Filling | Patents | 6 employees

(US) Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

cancer treatment pancreatic

add to watch list Paper trade email alert is off

Unicycive Therapeutics Inc

UNCY | $1.08 -0.92% -0.93% 230K

Professional, Scientific, and T...

(0.0% 1d) (-19.5% 1m) (-34.8% 1y) (-1.8% 2d) (-7.8% 3d) (-6.1% 7d) (-74.14% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 37,536,951
https://unicycive.com
Sec Filling | Patents | 2021 employees

Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

treatment kidney

add to watch list Paper trade email alert is off

Alpha Teknova Inc

TKNO | $2.09 3.98% 3.83% 2.8K

Professional, Scientific, and T...

(0.0% 1d) (-20.9% 1m) (-2.9% 1y) (0.0% 2d) (-5.2% 3d) (-17.4% 7d) (-62.87% volume)
Earnings Calendar: 2024-03-11
Market Cap: $ 85,320,879
https://www.teknova.com
Sec Filling | Patents | 193 employees

Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale across all stages of development, including commercialization.

diagnostics gene therapies t-cell

add to watch list Paper trade email alert is off